SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 2.0% Passive Stake in Artiva Biotherapeutics

BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G, reporting a 2.0% passive beneficial ownership stake in Artiva Biotherapeutics, Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 485,727 shares of Artiva Biotherapeutics, Inc. common stock.
• This represents 2.0% of the total outstanding common shares of Artiva Biotherapeutics, Inc.
• BlackRock holds sole voting power over 483,016 shares and sole dispositive power over 485,727 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Artiva Biotherapeutics.
• The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of a passive ownership stake by a large institutional investor, BlackRock, in Artiva Biotherapeutics. It does not contain performance data or strategic announcements from the issuer, thus maintaining a neutral sentiment regarding the issuer's operations.

Positives

• BlackRock's passive investment indicates a vote of confidence in Artiva Biotherapeutics as a long-term holding.
• The investment is held in the ordinary course of business, suggesting a standard portfolio allocation rather than an activist position.

Negatives

• The 2.0% stake is below the 5% threshold, meaning BlackRock is not required to disclose individual subsidiaries holding 5% or more, which limits transparency on specific fund holdings.
• The filing does not provide insights into Artiva Biotherapeutics' operational or financial performance.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of Artiva Biotherapeutics, indicating BlackRock will not be an activist investor.
• No single person's interest in the common stock of Artiva Biotherapeutics held by BlackRock is more than five percent of the total outstanding common shares.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant institutional investor, BlackRock, holds a passive stake in Artiva Biotherapeutics. Such filings are common for large asset managers who acquire shares in the ordinary course of business for their various funds and clients, without intending to influence the management or control of the company. It reflects a standard portfolio allocation rather than a strategic or activist investment.

Comparison to Industry Standards

• BlackRock's 2.0% stake in Artiva Biotherapeutics is a typical passive institutional holding, falling below the 5% threshold that would trigger more detailed reporting or suggest an activist intent, similar to how other large asset managers like Vanguard or State Street manage their diversified portfolios.
• The explicit statement that the holding is not for control aligns with the standard passive investment strategies of major index and mutual fund providers, distinguishing it from activist investor filings (e.g., Schedule 13D filings by firms like Elliott Management or Starboard Value).
• The beneficial ownership structure, with sole voting and dispositive power, is standard for institutional investors managing client assets.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's stake, potentially offering some confidence through BlackRock's investment.
• Employees, Customers, Suppliers, Creditors: Minimal direct impact as the filing is a passive ownership disclosure and does not relate to operational changes or financial performance.

Key Dates

Keywords

Artiva Biotherapeutics, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing, Biotechnology